Archives
- 2018-07
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
-
We also found that the size of
2023-01-02
We also found that the size of mEPSC amplitude was reduced in unc-43 mutants, consistent with the decrease in synaptic GLR-1/GLR-2 heteromeric receptors. The decrease in mEPSC amplitude was not as great as that observed when measuring current in response to pressure application of glutamate. These d
-
PKA signalling in the http
2023-01-02
PKA signalling in the nucleus was thought to be due to the translocation of the catalytic subunit upon activation from the MMP-2 Inhibitor II to the nucleus via diffusion [72]. However, a new understanding has emerged, as both the regulatory and catalytic subunits have been identified in the nucleu
-
br Concluding remarks Following the disappointing
2023-01-02
Concluding remarks Following the disappointing outcomes of Aβ immunotherapy trials for AD [62], the current prevailing concept is that disease-modifying therapy must be initiated from the presymptomatic stage of the disease because of the presumed incurability of chronic diseases once they become
-
Synthesis pharmacological evaluation for the binding at hA
2023-01-02
Synthesis, pharmacological evaluation for the binding at hA, hA and hA ARs, and efficacy at hA subtype of the synthesized compounds, together with the assessment of their theoretical ADME properties were the guidelines in this preliminary drug discovery investigation. The synthetic pathways which y
-
br Materials and methods br Results br Discussion Cdc has
2023-01-02
Materials and methods Results Discussion Cdc42 has been implicated in mediating the entry of HCV into hepatocytes, but how Cdc42 affects the response of HCV patients to IFN therapy is unknown. This study therefore examined the genetic association between Cdc42-related genes and efficacy of
-
We have expressed the ECDs of
2023-01-02
We have expressed the ECDs of the human α1, β1, γ and ɛ AChR subunits in the past using the methylotropic yeast Pichia pastoris as soluble glycosylated proteins [15], [16]. Further work with the γ subunit ECD revealed a marked improvement of the solubility and yield following the mutation of hydroph
-
The geometry of two three four and
2023-01-02
The geometry of two, three, four and five cpi 1 neutral radical ACh molecule complexes with various electronic configurations, i.e. with various multiplicities equal to 1, 2 and 4 (for ACh trimer) were determined using DFT with the unrestricted B97d/SVP potential/basis set in Gaussian09 program pack
-
The current guidelines are designed to optimize
2022-12-21
The current guidelines are designed to optimize the detection of IHC+FISH+ cases, most of which (but not all encountered in our study) being classically good responders to crizotinib therapy (resistance mechanisms to crizotinib therapy were not investigated in our study). In addition to the current
-
The current guidelines are designed to optimize
2022-12-21
The current guidelines are designed to optimize the detection of IHC+FISH+ cases, most of which (but not all encountered in our study) being classically good responders to crizotinib therapy (resistance mechanisms to crizotinib therapy were not investigated in our study). In addition to the current
-
The current guidelines are designed to optimize
2022-12-21
The current guidelines are designed to optimize the detection of IHC+FISH+ cases, most of which (but not all encountered in our study) being classically good responders to crizotinib therapy (resistance mechanisms to crizotinib therapy were not investigated in our study). In addition to the current
-
Increasing evidence indicates that ILCs participate in
2022-12-21
Increasing evidence indicates that ILCs participate in a dialog with CD4+ T atm inhibitor [107–110]. This dialog is mediated, in part, through the expression of type II major histocompatibility complex (MHCII) molecules on ILC3s [107]. Depending on the expression of co-stimulatory molecules, MHCII:T
-
br The AHR functions in the immune
2022-12-21
The AHR functions in the immune system – a tsunami of exciting findings The research of recent years has convincingly established an important function of the AHR in linking chemical environmental cues to immune responses [21,22], and reviewed in [1,23]. As a side effect, a view of the AHR as “Th
-
It is reported that Adiponectin is able to suppress NF
2022-12-21
It is reported that Adiponectin is able to suppress NF-κB pathway, and Bcr-Abl fusion oncoprotein in CML activates NF-κB by stimulating its nuclear translocation and also by enhancing its transactivation function [25], [26]. Therefore, it is tempting to hypothesize that NF-κB pathway might be involv
-
Moreover an increase of extracellular calcium stimulates BMP
2022-12-21
Moreover, an increase of extracellular calcium stimulates BMP-2 expression of pulp DMAP mg via L-type calcium channel and ERK signaling, which can be attenuated by PD98059 and nifedipine . Dental pulp cells expressed little calcium-sensing receptors . immunohistochemistry staining also shows the s
-
BV6 A more versatile cellular delivery system for adenosine
2022-12-21
A more versatile cellular delivery system for adenosine was generated by engineering mouse embryonic stem cells to lack both BV6 of Adk (Fedele et al., 2004). Using a step-wise differentiation protocol (Okabe et al., 1996) Adk−/− ES cells were differentiated into transplantable adenosine-releasing
14948 records 347/997 page Previous Next First page 上5页 346347348349350 下5页 Last page